CSL Valuation

Is CSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CSL (A$278.2) is trading below our estimate of fair value (A$330.36)

Significantly Below Fair Value: CSL is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSL?

Other financial metrics that can be useful for relative valuation.

CSL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue7.2x
Enterprise Value/EBITDA23.2x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does CSL's PE Ratio compare to its peers?

The above table shows the PE ratio for CSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average61.4x
CUV Clinuvel Pharmaceuticals
25.4x12.9%AU$766.9m
VRTX Vertex Pharmaceuticals
28.7x10.1%US$117.9b
GILD Gilead Sciences
164.2x36.5%US$81.8b
REGN Regeneron Pharmaceuticals
27.2x12.5%US$106.3b
CSL CSL
36.1x14.7%AU$134.4b

Price-To-Earnings vs Peers: CSL is good value based on its Price-To-Earnings Ratio (36.1x) compared to the peer average (61.4x).


Price to Earnings Ratio vs Industry

How does CSL's PE Ratio compare vs other companies in the Global Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: CSL is expensive based on its Price-To-Earnings Ratio (36.1x) compared to the Global Biotechs industry average (28.9x).


Price to Earnings Ratio vs Fair Ratio

What is CSL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio36.1x
Fair PE Ratio40.1x

Price-To-Earnings vs Fair Ratio: CSL is good value based on its Price-To-Earnings Ratio (36.1x) compared to the estimated Fair Price-To-Earnings Ratio (40.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CSL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$278.20
AU$306.93
+10.3%
8.3%AU$334.06AU$228.87n/a16
May ’25AU$274.49
AU$306.02
+11.5%
9.5%AU$339.01AU$232.45n/a16
Apr ’25AU$287.92
AU$304.07
+5.6%
9.0%AU$341.20AU$232.95n/a16
Mar ’25AU$282.35
AU$301.73
+6.9%
9.0%AU$334.83AU$231.44n/a16
Feb ’25AU$296.76
AU$321.83
+8.4%
6.3%AU$352.41AU$278.23n/a15
Jan ’25AU$286.65
AU$308.65
+7.7%
4.3%AU$343.39AU$288.82n/a16
Dec ’24AU$262.86
AU$311.54
+18.5%
4.1%AU$349.56AU$294.01n/a16
Nov ’24AU$234.98
AU$323.64
+37.7%
4.8%AU$361.36AU$300.30n/a16
Oct ’24AU$250.80
AU$328.43
+31.0%
4.0%AU$361.13AU$300.11n/a16
Sep ’24AU$269.09
AU$326.82
+21.5%
5.8%AU$360.64AU$270.09n/a18
Aug ’24AU$269.32
AU$325.65
+20.9%
6.2%AU$352.98AU$261.58n/a18
Jul ’24AU$277.38
AU$326.90
+17.9%
6.2%AU$349.81AU$259.04n/a18
Jun ’24AU$310.29
AU$352.10
+13.5%
6.9%AU$376.39AU$265.34n/a18
May ’24AU$302.43
AU$338.98
+12.1%
7.1%AU$361.57AU$254.89AU$274.4917
Apr ’24AU$288.30
AU$341.11
+18.3%
7.0%AU$365.29AU$257.73AU$287.9217
Mar ’24AU$292.85
AU$340.93
+16.4%
7.1%AU$362.93AU$256.06AU$282.3517
Feb ’24AU$301.52
AU$314.46
+4.3%
7.7%AU$345.52AU$248.58AU$296.7616
Jan ’24AU$287.76
AU$319.60
+11.1%
6.4%AU$347.91AU$265.12AU$286.6516
Dec ’23AU$298.66
AU$309.44
+3.6%
6.2%AU$338.25AU$260.23AU$262.8616
Nov ’23AU$283.26
AU$316.32
+11.7%
4.6%AU$336.58AU$277.21AU$234.9816
Oct ’23AU$285.02
AU$332.05
+16.5%
7.4%AU$366.50AU$272.96AU$250.8016
Sep ’23AU$293.79
AU$325.05
+10.6%
6.7%AU$350.79AU$261.25AU$269.0917
Aug ’23AU$294.91
AU$313.27
+6.2%
7.9%AU$342.64AU$240.24AU$269.3215
Jul ’23AU$269.23
AU$314.99
+17.0%
7.9%AU$364.35AU$244.27AU$277.3815
Jun ’23AU$273.50
AU$317.42
+16.1%
9.2%AU$358.61AU$240.42AU$310.2915
May ’23AU$273.30
AU$312.07
+14.2%
8.8%AU$348.56AU$228.85AU$302.4315

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.